# Alphabet’s Isomorphic Labs seeks funding at $40 billion valuation

> Alphabet’s AI drug‑discovery unit is in talks for new money, aiming for a $40 billion valuation.

Oossa · 2026-10-08 · https://oossa.com/en/alphabet-s-isomorphic-labs-seeks-funding-at-40-billion-valuation

Alphabet’s Isomorphic Labs, the AI‑driven biolab led by Nobel laureate Demis Hassabis, is reportedly negotiating a new funding round that would value the company at $40 billion. The fresh capital is meant to speed up its drug‑development programs. Other AI firms such as China’s DeepSeek, Moonshot and OpenAI are also chasing large investments, showing high market interest in AI despite warnings of a possible bubble.

## The facts

- Valuation target: $40 billion
- Report date: Thu Oct 08 2026

## Why it matters

If the financing closes, Isomorphic Labs could bring AI‑designed medicines to market faster, affecting patients and pharma partners.

## Sources & references

1. [Alphabet’s biolab in funding talks at $40B valuation](https://www.semafor.com/article/10/08/2026/alphabets-biolab-in-funding-talks-at-40b-valuation) – Semafor, 2026-10-08
2. [Alphabet spinoff Isomorphic Labs reportedly raising funding at up to $50B valuation](https://siliconangle.com/2026/10/08/alphabet-spinoff-isomorphic-labs-reportedly-raising-funding-at-up-to-50b-valuation/) – SiliconANGLE, 2026-10-08

Last updated: 2026-10-08